Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 7/20 | 0.32 |
| ▸ | BPTF | Q12830 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778184 | 0.77 | ADRA1D (0.37) | — | |
| SCHEMBL13170185 | 0.72 | CHRM1 (0.53) | CHRM1DPP4 | |
| SCHEMBL10210786 | 0.69 | JAK2 (0.41) | CHRM1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL21946382 | 0.69 | JAK2 (0.41) | CHRM1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL10210762 | 0.69 | JAK2 (0.41) | CHRM1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL15998464 | 0.67 | KAT2B (0.35) | KAT2BBPTF | |
| Pyrrolidine SCHEMBL7083927 | 0.66 | CHRM1 (0.47) | CHRM1 | |
| SCHEMBL6779518 | 0.66 | CHRM1 (1.00) | CHRM1 | |
| Piperidine SCHEMBL7088590 | 0.65 | CHRM1 (0.46) | CHRM1 | |
| SCHEMBL6776793 | 0.65 | CHRM1 (0.49) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6759419-B2 | NOOTROPIC AGENTS; BRAIN DISORDERS; ALZHEIMER'S DISEASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-07-06 | — | — | US | claimed |
| US-20030114491-A1 | Pyrrolidinone derivatives, their preparation and pharmaceutical composition comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-06-19 | — | — | US | claimed |
| US-6759419-B2 | NOOTROPIC AGENTS; BRAIN DISORDERS; ALZHEIMER'S DISEASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-07-06 | — | — | US | disclosed |
| US-20030114491-A1 | Pyrrolidinone derivatives, their preparation and pharmaceutical composition comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114491-A1 | Pyrrolidinone derivatives, their preparation and pharmaceutical composition comprising the same | CHRM1, CHRNA5, CHRNA7 | CHRM1 1/4885DPP4 2159/4885KAT2B 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.